Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAVIO
NCT04747197Phase 1Completed
- Sponsor
- EyePoint Pharmaceuticals
- Start
- Jan 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vorolanib in exudative macular degeneration (3 arms), sponsored by EyePoint Pharmaceuticals. Primary endpoint: Incidence of ocular (study eye) and systemic treatment emergent adverse events (TEAEs) at Week 48. Started Jan 2021; status: completed.
02
Drugs
vorolanib
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT04747197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04747197.